Profound Medical Corp.
NASDAQ:PROF · NASDAQ Capital Market
+$0.27 today
Vol 0.09M · Avg 0.12M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.6%
avg -71.7%
ROIC
-22.7%
avg -53.8%
ROA
-22.4%
avg -48.6%
Analysis
ROA is currently the strongest return metric at -22.4% versus its period average of -48.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Arun Swarup Menawat | Chairman of the Board & Chief Executive Officer | $998,593.00 | — | 71 | $587,089.00 | 1.94% |
Mathieu Burtnyk | President | $479,836.00 | — | 44 | — | — |
Rashed Dewan | Chief Financial Officer | $472,272.00 | — | 58 | — | — |
Thomas Tamberrino | Chief Commercial Officer | $382,200.00 | — | 46 | — | — |
Matthew Sobczyk | Assistant Corporate Controller | — | — | — | — | — |
Stephen Kilmer | Investor Relations | — | — | — | — | — |
Levant Tinaz | Software Developer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$348.20M
Prenetics Global Limited
NASDAQ:PRE
$343.75M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$258.44M
Perspective Therapeutics, Inc.
AMEX:CATX
$232.14M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$147.66M
MaxCyte, Inc.
NASDAQ:MXCT
$125.90M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$119.35M
Owlet, Inc.
NYSE:OWLT
$90.11M
Neuronetics, Inc.
NASDAQ:STIM
$84.61M
LENSAR, Inc.
NASDAQ:LNSR
$71.05M
Who manages PROF?
Profound Medical Corp. (PROF) lists 7 active executives. The top listed executive is Arun Swarup Menawat, Chairman of the Board & Chief Executive Officer.
Are PROF insiders buying or selling?
Recent insider activity shows net buying of $90,350.69.
Explore More
Continue the stock analysis
Jump to another research area for this company.